The Evolving Landscape of COVID-19: Factors Associated with In-hospital COVID-19 Related Mortality During the 2023-2024 Phase of JN.1 Subvariant Dominance

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Date 2025 Jan 28

PMID 39871210

Authors

Drieda Zace

Albiana Cekrezi

Christopher Jones

Ludovica Ferrari

Giuseppe De Simone

Elisabetta Teti

Vincenzo Malagnino

Marco Iannetta

Loredana Sarmati

Anna Maria Geretti

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19 remains a complex health challenge. We analysed the characteristics and outcomes of COVID-19-related hospitalisations during JN.1 variant dominance.

Methods: Conducted in a hospital serving a socioeconomically deprived population, this study included all adults hospitalised with COVID-19 from 1st November 2023 to 31st August 2024. The primary outcome was in-hospital mortality, analysed in relation to demographic, clinical, and laboratory parameters.

Results: Among 122 individuals (median age 76 years, 58.2% males, median comorbidity index 5), 114/122 (93.4%) had received ≥ 1 SARS-CoV-2 vaccination, with a median of 23 months elapsed since the last dose. Fever (67/122, 54.9%) and dyspnoea (49/122, 40.2%) were common presenting symptoms, with 78/122 (64%) showing CT evidence of SARS-CoV-2 pneumonia; 25/122 (20%) had purely neurological presentations. Treatment included remdesivir (115/122, 94.3%) and/or nirmatrelvir/ritonavir (9/122, 7.4%), sotrovimab (15/122, 12.3%), corticosteroids (61/122, 50.0%), and oxygen supplementation (76/122, 62.3%). Whereas 107/122 (87.7%) were discharged after a median of seven days, in-hospital mortality was 15/122 (12.3%) after a median of 16 days. Baseline factors associated with mortality were neutrophil-lymphocyte ratio > 8, D-dimer ≥ 1800 ng/mL, procalcitonin ≥ 1.0 ng/mL, and albumin < 3.2 g/dL; during admission, nasopharyngeal SARS-CoV-2 antigen positivity persisting for > 12 days, hospitalisation for ≥ 10 days, higher oxygen requirements with the resulting corticosteroid use, and healthcare-associated bacteraemia were associated with increased odds of mortality.

Conclusions: Baseline laboratory parameters and persistent SARS-CoV-2 antigen positivity despite antiviral therapy offer readily available prognostic insights for patients hospitalised with COVID-19. It is imperative to advocate for up-to-date COVID-19 vaccination among older people and other vulnerable groups.

References

Bordino V, Vicentini C, DAmbrosio A, Quattrocolo F, Zotti C . Burden of healthcare-associated infections in Italy: incidence, attributable mortality and disability-adjusted life years (DALYs) from a nationwide study, 2016. J Hosp Infect. 2021; 113:164-171. DOI: 10.1016/j.jhin.2021.04.023. View

Rotundo S, Berardelli L, Gulli S, La Gamba V, Lionello R, Russo A . Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study. BMC Infect Dis. 2024; 24(1):564. PMC: 11155142. DOI: 10.1186/s12879-024-09466-y. View

Gan Y, Zhang G, Sun H, Lyu X . Clinical characteristics and risk factors for bacterial co-infections in COVID-19 patients: A retrospective study. J Glob Antimicrob Resist. 2024; 38:6-11. DOI: 10.1016/j.jgar.2024.04.007. View

Kinsella P, Moso M, Morrissey C, Dendle C, Guy S, Bond K . Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review. Transpl Infect Dis. 2024; 26(3):e14301. DOI: 10.1111/tid.14301. View

Westblade L, Simon M, Satlin M . Bacterial Coinfections in Coronavirus Disease 2019. Trends Microbiol. 2021; 29(10):930-941. PMC: 8026275. DOI: 10.1016/j.tim.2021.03.018. View

Rajme-Lopez S, Martinez-Guerra B, Roman-Montes C, Tamez-Torres K, Tello-Mercado A, Tepo-Ponce K . Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study. Ther Adv Infect Dis. 2024; 11:20499361241236582. PMC: 10966993. DOI: 10.1177/20499361241236582. View

Fan H, Zhou L, Lv J, Yang S, Chen G, Liu X . Bacterial coinfections contribute to severe COVID-19 in winter. Cell Res. 2023; 33(7):562-564. PMC: 10204009. DOI: 10.1038/s41422-023-00821-3. View

Fabiani M, Mateo-Urdiales A, Sacco C, Fotakis E, Battilomo S, Petrone D . Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different.... Vaccine. 2024; 42(23):126026. DOI: 10.1016/j.vaccine.2024.05.074. View

Patton M, Orihuela C, Harrod K, Bhuiyan M, Dominic P, Kevil C . COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Crit Care. 2023; 27(1):34. PMC: 9868503. DOI: 10.1186/s13054-023-04312-0. View

10.

Visentin A, Pickavance E, San-Juan R, Grossi P, Manuel O, Aguado J . Current management of SARS-CoV-2 infection in solid organ transplant recipients: Experience derived from an ESGICH-ESOT survey. Transpl Infect Dis. 2024; 26(2):e14252. DOI: 10.1111/tid.14252. View

11.

Calderon-Parra J, Gutierrez-Villanueva A, Ronda-Roca G, Jimenez M, de la Torre H, Rodenas-Baquero M . Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study. Int J Antimicrob Agents. 2024; 63(3):107095. DOI: 10.1016/j.ijantimicag.2024.107095. View

12.

Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto H, Pelosi P, Rocco P . Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. Front Immunol. 2022; 13:857573. PMC: 9091347. DOI: 10.3389/fimmu.2022.857573. View

13.

Park J, Cho H, Jeon C, Kim S, Park I, Kim K . Characteristics and biomarkers associated with mortality in COVID-19 patients presenting to the emergency department. Epidemiol Infect. 2024; 152:e76. PMC: 11094378. DOI: 10.1017/S0950268824000633. View

14.

Aziz M, Fatima R, Lee-Smith W, Assaly R . The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020; 24(1):255. PMC: 7249975. DOI: 10.1186/s13054-020-02995-3. View

15.

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

16.

Bell C, Gibbons D, Drysdale M, Birch H, Lloyd E, Patel V . Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PLoS One. 2024; 19(7):e0304822. PMC: 11251586. DOI: 10.1371/journal.pone.0304822. View

17.

Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu N, Chuenkitmongkol S . Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines. 2022; 22(1):1-16. DOI: 10.1080/14760584.2023.2143347. View

18.

Link-Gelles R, Levy M, Natarajan K, Reese S, Naleway A, Grannis S . Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023; 6(3):e232598. PMC: 10018321. DOI: 10.1001/jamanetworkopen.2023.2598. View

19.

Wu T, Chen P, Wang J, Liu W, Chen Y, Chang S . Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients. J Antimicrob Chemother. 2024; 79(5):1196-1200. DOI: 10.1093/jac/dkae082. View

20.

Choi M, Wan E, Wong I, Chan E, Chu W, Tam A . Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study. Lancet Infect Dis. 2024; 24(11):1213-1224. DOI: 10.1016/S1473-3099(24)00353-0. View